MedTrace Logo

Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?

NCT03954873 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-11-04

No results posted yet for this study

Summary

Infusion of glucagon-like peptide 2 (GLP-2) during euglycaemia, hypoglycaemia and hyperglycaemia and evaluation of the effect on glucagon secretion in healthy subjects.

Conditions

  • Glucose Metabolism Disorders
  • Endocrine or Metabolic Disease

Interventions

OTHER

Glucagon-like peptide 2

Human glucagon-like peptide 2

OTHER

Saline

Placebo

OTHER

Glucose

20% (w/v) glucose infusion for regulating plasma glucose

OTHER

Insulin

Actrapid (insulin) for lowering plasma glucose

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Filip Krag Knop, MD, PhD · Center for Clinical Metabolic Research

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2020-06-01
Completion
2020-06-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03954873 on ClinicalTrials.gov